FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 21 - Any |
| Updated: | 9/1/2017 |
| Start Date: | May 2013 |
| End Date: | August 29, 2017 |
This study has been designed to help us determine if FACBC PET or PEM can accurately evaluate
how far the breast cancer has spread in the breast. Also, to help determine if FACBC PET or
PEM can accurately measure your response to chemotherapy.
how far the breast cancer has spread in the breast. Also, to help determine if FACBC PET or
PEM can accurately measure your response to chemotherapy.
Inclusion Criteria:
- Women presenting for evaluation at MSKCC with biopsy proven primary IDC or ILC
- No prior therapy for IDC or ILC
- Clinical need for local disease staging with breast MR (Group A only)
- Clinical need for neoadjuvant chemotherapy (Group B only)
- Patients must provide written informed consent
Exclusion Criteria:
- Age <21 years
- Men
- Pregnancy or lactation
- Patients who have already started treatment for the current malignancy
- Patients who cannot undergo PET scanning (i.e. because of weight limits)
- Patients who are known to have contraindication for MRI (e.g. metal implants)
- Patients may only participate in group #1 or group #2, but not both
We found this trial at
1
site
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
